联合治疗在克罗恩病中的益处取决于疾病表型和病程
该多中心前瞻性队列纳入707例克罗恩病和164例溃疡性结肠炎患者,比较抗TNF单药与联合免疫调节剂治疗。联合治疗在总体克罗恩病和溃疡性结肠炎中未显著降低1年复合不良结局,但在狭窄型或穿透型克罗恩病及病程<5年者中观察到显著获益,且英夫利西单抗与其他抗TNF生物制剂效果相似。
要点
- 联合治疗在总体克罗恩病(OR 0.87,95%CI 0.63-1.22)和溃疡性结肠炎(OR 1.45,95%CI 0.63-3.38)中未显著降低1年复合结局。
- 狭窄型或穿透型克罗恩病患者联合治疗组结局发生率为30%,低于未联合组的39%(OR 0.58,95%CI 0.37-0.90)。
- 病程<5年的克罗恩病患者联合治疗OR为0.35(95%CI 0.14-0.87),优于病程较长者的OR 0.75(95%CI 0.45-1.27)。
核心结论
- 联合免疫调节剂-生物制剂治疗的益处在复杂型克罗恩病中更强,尤其是在疾病早期。
研究设计与样本
- 多中心前瞻性队列研究,纳入707例克罗恩病患者(45%接受联合治疗)和164例溃疡性结肠炎患者(38%接受联合治疗)。
- 将患者分为抗TNF单药治疗组和联合免疫调节剂治疗组,主要结局为1年内新发IBD相关手术、住院、穿透性并发症、需要使用糖皮质激素或新生物制剂的复合结局。
- 采用多变量回归模型校正潜在混杂因素。
主要发现
- 联合治疗与克罗恩病复合结局降低无关(OR 0.87,95%CI 0.63-1.22),与溃疡性结肠炎复合结局降低也无关(OR 1.45,95%CI 0.63-3.38)。
- 在非狭窄非穿透型克罗恩病患者中未见差异,而在狭窄型或穿透型克罗恩病患者中,联合治疗组结局发生率为30%,未联合组为39%(OR 0.58,95%CI 0.37-0.90)。
- 病程<5年的克罗恩病患者联合治疗OR为0.35(95%CI 0.14-0.87),病程较长者OR为0.75(95%CI 0.45-1.27)。
- 英夫利西单抗与其他抗TNF生物制剂在复合结局发生率上观察到相似的降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of combination therapy on disease-related morbidity in patients with established Crohn's disease (CD) or ulcerative colitis (UC) remains to be well-defined. AIM: To examine the effect of combination therapy on disease outcomes in CD and UC. METHODS: Using a multicenter prospective cohort, we classified CD and UC patients as being on monotherapy with anti-TNF or on combination with an immunomodulator. The primary outcome was a composite of new IBD-related surgery, hospitalisations, penetrating complications, need for corticosteroids or new biological at 1 year. Multivariable regression models adjusted for potential confounders. RESULTS: We included 707 patients with CD (45% combination therapy) and 164 with UC (38% combination therapy). Combination therapy was not associated with reduction in the composite outcome in either CD (OR: 0.87, 95% CI: 0.63-1.22) or UC (OR: 1.45, 95% CI: 0.63-3.38). However, while no difference was noted in those with nonstricturing, nonpenetrating CD, a significant reduction in the likelihood of the outcome was seen in those with stricturing or penetrating CD (30% vs 39%, OR: 0.58, 95% CI: 0.37-0.90). A stronger effect was also observed in those with disease duration <5 years (OR: 0.35, 95% CI: 0.14-0.87) compared to those with a longer duration (OR: 0.75, 95% CI: 0.45-1.27). A similar reduction in occurrence of composite outcome was noted with infliximab and with other anti-TNF biologics. CONCLUSION: The benefit of combination immunomodulator-biological therapy is stronger in those with complicated Crohn's disease, particularly early on in their disease course.
引用
- Ananthakrishnan AN, Sakuraba A, Barnes EL, et al. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther. 2017. PMID: 28470787. doi:10.1111/apt.14125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。